The NCI SBIR provides funding and non-funding support to small businesses and entrepreneurs developing novel cancer technologies.

For FY 25, there are funding opportunities for 13 different Contract Topics:

·     NIH/NCI 466 – Novel Delivery Systems for RNA-based Cancer Vaccines

·     NIH/NCI 467 – Development of Cancer Immunoprevention Agents

·     NIH/NCI 468 – Synthetic Microbes (Excluding Oncolytic Viruses) for Immuno-Oncology Therapies

·     NIH/NCI 469 – Development of Novel Therapeutics for HPV-related Precancer

·     NIH/NCI 470 – Precision Nutrition Interventions to Reduce Cancer-Related Symptoms

·     NIH/NCI 471 – Drug-Loaded Carrier Particles for Improved Oral Delivery for Colon Cancer Prevention

·     NIH/NCI 472 – Antibody-Drug Conjugates as Radiopharmaceutical Theranostics for Cancer

·     NIH/NCI 473 – Point of Care Detection of Antibodies Against HPV16/18 E6 and E7 Oncoproteins in Oropharyngeal Cancer

·     NIH/NCI 474 – Point of Care Technologies for GI Cancer Prevention and Early Detection

·     NIH/NCI 475 – Development of Digital Biomarkers and Endpoints for Clinical Cancer Care

·     NIH/NCI 476 – Digital Twin Software for Optimization of Cancer Radiation Therapy 

·     NIH/NCI 477 – Wearable Technologies to Facilitate Remote Monitoring of Cancer Patients Following Treatment·    

NIH/NCI 478 – Advanced Biomaterials to Improve Cancer Modeling for Research

To learn more about these opportunities, click on the topic links or visit the SBIR page here.